DOD Tuberous Sclerosis Complex, Idea Development Award | W81XWH 21 TSCRP IDA

Frequently Asked Questions (FAQs)

What is the name of this funding opportunity?

This opportunity is the Department of Defense (DoD) Tuberous Sclerosis Complex (TSC) Research Program (TSCRP) Idea Development Award (IDA).

What is the funding opportunity number?

The funding opportunity number is W81XWH-21-TSCRP-IDA.

Which agency and office are offering this opportunity?

The Department of Defense (DoD) is offering the opportunity through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the main purpose of the TSCRP Idea Development Award?

The Idea Development Award is intended to support conceptually innovative, hypothesis-driven research aimed at generating high-impact advances in TSC research and, ultimately, improving outcomes and care for people living with TSC.

What kinds of projects does the Idea Development Award prioritize?

The award prioritizes projects that open new directions in the TSC field rather than projects that simply extend existing work. The emphasis is on ideas with the potential to yield high-impact findings and create new avenues of investigation.

Is this opportunity focused on basic science, clinical research, or something else?

Based on the summary provided, the program supports science and technology and other research and development efforts in TSC, with an emphasis on advancing TSC biology, diagnosis, treatment approaches, and/or patient care practices. Specific research scope details beyond that are not provided in the excerpt.

Is this a grant or a cooperative agreement?

The mechanism is offered as a grant or cooperative agreement. This means awards may be structured either as standard financial assistance (grant) or with a more active federal partnership (cooperative agreement), depending on project needs and the government role.

What does it mean that awards may be grants or cooperative agreements?

It means some projects may be funded as standard grants, while others may involve more active involvement by the federal government through a cooperative agreement. The summary indicates the structure may depend on the project needs and intended government role, but it does not specify how that determination is made.

What are the key review priorities for this award?

The opportunity emphasizes three key review priorities: impact, innovation, and preliminary data.

What does “impact” mean in this program?

Impact is described as central to competitiveness. Applicants are expected to explain the short-term and long-term significance of the work and make a clear case that successful results would meaningfully advance TSC biology, diagnosis, treatment approaches, or patient care practices, rather than producing narrow or incremental insights.

What level of “innovation” is expected?

Innovation is required and is defined practically: the project should introduce or support a new paradigm, challenge existing assumptions, or approach an established problem from a fresh perspective. The program explicitly indicates that “the next logical step” or incremental advances do not meet the innovation bar.

Are high-risk, high-reward projects allowed?

Yes. The program leaves room for high-risk, high-reward approaches, as long as the concepts are strong and appropriately justified.

Does the application need a hypothesis?

Yes. Proposals are expected to be grounded in a well-formulated, testable hypothesis and supported by a strong scientific rationale.

Can purely speculative ideas be submitted?

The award emphasizes innovation, but it is not intended for purely speculative concepts without evidence. The work should be ready to be tested in a rigorous, hypothesis-driven way.

Are preliminary data required?

Yes. Preliminary data are expected as part of this opportunity.

What types of preliminary data are considered acceptable?

The opportunity anticipates unpublished findings from the principal investigator’s lab or named collaborators and/or relevant evidence drawn from the published literature. The aim is to demonstrate feasibility and grounding in evidence, even when the core idea is bold and novel.

How many awards are anticipated?

The opportunity anticipated making about four awards.

Who is eligible to apply?

Eligibility is listed as unrestricted, meaning it is open to any type of applicant organization unless additional eligibility constraints are stated elsewhere in the full announcement.

What is the CFDA listing for this opportunity?

The Catalog of Federal Domestic Assistance (CFDA) listing is 12.420.

What are the key dates listed in the summary?

The posting date is April 1, 2021, and the original closing date is July 8, 2021.

Is the maximum award amount (award ceiling) provided?

The listing shows an award ceiling of 0, which typically signals that the maximum award amount is not specified in the summary and would need to be confirmed in the full funding announcement or associated program guidance.

Does the summary specify a minimum award amount or a typical award size?

No. The provided information does not include a minimum award amount, a typical award size, or a specified ceiling amount beyond noting that the award ceiling is shown as 0 in the listing summary.

What should a competitive application emphasize overall?

Based on the summary, a competitive application should present a testable hypothesis supported by a strong rationale, include preliminary data to establish feasibility, clearly articulate short- and long-term impact for the TSC field and patient care, and demonstrate genuine innovation (not incremental “next step” work).